A brief summary of the CMS Coding 2021 – AAOA Zoomcast Series: Just In Time Content for AAOA Members, Part II. Written by Christie DeMason MD, FAAOA. Panelists: James Connolly, MD; Ayesha Khalid, MD, MBA; Nalin Patel, MD; Robert Stachler,…
“Peanut allergy affects approximately 1 million children in the U.S. and only 1 out of 5 of these children will outgrow their allergy. Because there is no cure, allergic individuals must strictly avoid exposure to prevent severe and potentially life-threatening reactions,” said Peter Marks, M.D., Ph.D., director of the FDA’s Center for Biologics Evaluation and Research. “Even with strict avoidance, inadvertent exposures can and do occur. When used in conjunction with peanut avoidance, Palforzia provides an FDA-approved treatment option to help reduce the risk of these allergic reactions in children with peanut allergy.”
On January 31st, the U.S. Food and Drug Administration (FDA) approved Palforzia [Peanut (Arachis hypogaea) Allergen Powder-dnfp] to mitigate allergic reactions, including anaphylaxis, that may occur with accidental exposure to peanuts.
Learn more at www.fda.gov.